Fear, Misconceptions Discourage International Hepatitis B and C Testing
In a large survey conducted across Africa, Asia, and Latin America, nearly a third of respondents said they had no interest in getting tested for hepatitis B virus (HBV) or hepatitis C virus (HCV). More than half of the respondents said they did not believe they were at risk for these viruses. These results offer […]
B/F/TAF Achieves Sustained HIV and HBV Suppression
At CROI 2025, Anchalee Avihingsanon, MD, PhD, principal investigator of the ALLIANCE study and researcher at the HIV-NAT at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand, discussed findings from the ALLIANCE trial. This Phase 3 study evaluated the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) compared to dolutegravir + emtricitabine/tenofovir disoproxil fumarate […]
Lassa Fever Vaccine Study Enrollment Begins
Scanning electron micrograph of Lassa virus budding off a cell. Lassa virus (LASV) is an arenavirus that causes Lassa hemorrhagic fever, a type of viral hemorrhagic fever (VHF) in humans and other primates.Image Credit: NIAID NIH announced today that enrollment has begun for participants in a Lassa fever vaccine study at the University of Maryland […]
Immunocore Reports 2/5 Participants Achieve Viral Control and HIV Reservoir Reduction Across 3 Dose Cohorts of IMC-M113V
Immunocore Holdings plc presented early findings from the multiple ascending dose (MAD) phase of its Phase 1/2 STRIVE trial for IMC-M113V at CROI 2025 in San Francisco, California. The data suggest that IMC-M113V, a T cell receptor bispecific therapy, is well tolerated and demonstrates signs of dose-dependent viral control after antiretroviral treatment (ART) interruption. The […]
Week of March 17, 2025
Captured on the 5th day of this illness, this photograph depicted a posterior view of the back of a patient with a case of measles, highlighting the characteristic erythematous rash that had manifested, and spread over this region. Note how the rash appeared to be a raised crop of irregularly shaped coalescing spots. Image credit: […]
Pay Today or Pay Tomorrow
Carl Schmid, executive director, HIV + Hepatitis Policy Institute Image credit: HIV + Hepatitis Policy Institute This is the third in a series on the State of HIV today. There is a lot going on with regards to public policy and legality of HIV care and prevention. For example, there is a case in the […]
The Business Sector’s Advocacy to Maintain Funding for HIV Prevention, Research, Treatment
This is the second in a series on the state of HIV today. In late February, The US Business Action to End HIV, the largest coalition of employers dedicated to ending the HIV epidemic in the United States, sent a letter to Congress urging them to prioritize sustained federal funding for HIV prevention and treatment […]
Apretude PrEP Shows High Efficacy, Safety in Diverse Studies
At this week’s CROI conference, ViiV Healthcare presented real-world data on its long-acting injectable PrEP, cabotegravir long-acting (CAB LA), (Apretude). In it’s PILLAR study, there was zero HIV acquisition through 12 months and high persistence with CAB LA for PrEP. These new 12-month findings from the examined the effectiveness, diagnostic testing, persistence (time that an […]
Ensitrelvir Prevents COVID-19 Infection as Post Exposure Prophylaxis
At this week’s CROI conference, Japan-based Sihonogi presented results for its investigational antiviral, ensitrelvir, that demonstrated a 67% reduction in the risk of developing COVID-19 in uninfected individuals treated after exposure, compared to a placebo at day 10.1 Of the study participants treated with ensitrelvir, 2.9% developed symptomatic COVID-19 compared to 9.0% of participants on […]
Pandemic Disruptions in HIV Care Impacted on Early ART Initiation and Viral Suppression
Sarita Shah, MD MPH Image credits: Emory University A study presented at CROI 2025 by Sarita Shah, MD, MPH, professor of epidemiology and global health at the Rollins School of Public Health, Emory University, examined the impact of the COVID-19 pandemic on early antiretroviral therapy (eART) initiation and viral suppression (eVS) among people with HIV […]
